Goldman Sachs’s BridgeBio Oncology BBOT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$982K Buy
239,614
+137,529
+135% +$1.07M ﹤0.01% 5255
2026
Q2
$778K Sell
102,085
-65,488
-39% -$547K ﹤0.01% 5410
2026
Q1
$1.5M Buy
167,573
+72,922
+77% +$783K ﹤0.01% 4777
2025
Q4
$1.19M Buy
+94,651
New +$1.15M ﹤0.01% 5006

Other funds holding BBOT

Goldman Sachs's BBOT Position: Q3 2026 in Review

Goldman Sachs increased its BridgeBio Oncology (BBOT) stake by 135% in Q3 2026, buying an estimated $1.07M and bringing the position to 239,614 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #5255.

Goldman Sachs first reported a position in BBOT in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.5M in Q1 2026. 89 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

  • Goldman Sachs held 239,614 shares of BridgeBio Oncology worth $982K as of Q3 2026.
  • Goldman Sachs bought 137,529 BridgeBio Oncology shares in Q3 2026, an estimated $1.07M.
  • BridgeBio Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5255 holding.
  • Goldman Sachs first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 4 quarters since.
  • Goldman Sachs's BridgeBio Oncology position peaked at $1.5M in Q1 2026.
  • 89 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.